Sipuleucel-T for the treatment of metastatic prostate cancer

References

• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277 - 300; http://dx.doi.org/10.3322/caac.20073; PMID: 20610543
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Feng Z, Trock BJ, Humphreys EB, Carducci MA, Partin AW, et al. The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. BJU Int 2012; 109:32 - 9; http://dx.doi.org/10.1111/j.1464-410X.2011.10422.x; PMID: 21777360
   PubMed Web of Science ®Google Scholar
• Uchio EM, Aslan M, Wells CK, Calderone J, Concato J. Impact of biochemical recurrence in prostate cancer among US veterans. Arch Intern Med 2010; 170:1390 - 5; http://dx.doi.org/10.1001/archinternmed.2010.262; PMID: 20696967
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA, et al. Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 2011; 108:378 - 85; http://dx.doi.org/10.1111/j.1464-410X.2010.09878.x; PMID: 21091976
   PubMed Web of Science ®Google Scholar
• D’Amico AV, Cote K, Loffredo M, Renshaw AA, Schultz D. Determinants of prostate cancer-specific survival after radiation therapy for patients with clinically localized prostate cancer. J Clin Oncol 2002; 20:4567 - 73; http://dx.doi.org/10.1200/JCO.2002.03.061; PMID: 12454114
   PubMed Web of Science ®Google Scholar
• Oh WK, Kantoff PW. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol 1998; 160:1220 - 9; http://dx.doi.org/10.1016/S0022-5347(01)62501-1; PMID: 9751323
   PubMed Web of Science ®Google Scholar
• Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377:813 - 22; http://dx.doi.org/10.1016/S0140-6736(10)62344-6; PMID: 21353695
   PubMed Web of Science ®Google Scholar
• de Bono JS, Oudard S, Ozguroglu M, Hansen S, Machiels JP, Kocak I, et al, TROPIC Investigators. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376:1147 - 54; http://dx.doi.org/10.1016/S0140-6736(10)61389-X; PMID: 20888992
   PubMed Web of Science ®Google Scholar
• de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, et al, COU-AA-301 Investigators. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995 - 2005; http://dx.doi.org/10.1056/NEJMoa1014618; PMID: 21612468
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Engl J Med 2011; 364:2055 - 8; http://dx.doi.org/10.1056/NEJMe1102758; PMID: 21612475
   PubMed Web of Science ®Google Scholar
• Coffey DS, Isaacs JT. Control of prostate growth. Urology 1981; 17:Suppl 3 17 - 24; PMID: 6163242
   PubMedGoogle Scholar
• Wang X, Yu J, Sreekumar A, Varambally S, Shen R, Giacherio D, et al. Autoantibody signatures in prostate cancer. N Engl J Med 2005; 353:1224 - 35; http://dx.doi.org/10.1056/NEJMoa051931; PMID: 16177248
   PubMed Web of Science ®Google Scholar
• Taylor BS, Varambally S, Chinnaiyan AM. Differential proteomic alterations between localised and metastatic prostate cancer. Br J Cancer 2006; 95:425 - 30; http://dx.doi.org/10.1038/sj.bjc.6603274; PMID: 16880794
   PubMed Web of Science ®Google Scholar
• Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 2002; 62:4427 - 33; PMID: 12154050
   PubMed Web of Science ®Google Scholar
• Arlen PM, Mohebtash M, Madan RA, Gulley JL. Promising novel immunotherapies and combinations for prostate cancer. Future Oncol 2009; 5:187 - 96; http://dx.doi.org/10.2217/14796694.5.2.187; PMID: 19284377
   PubMed Web of Science ®Google Scholar
• Drake CG, Jaffee E, Pardoll DM. Mechanisms of immune evasion by tumors. Adv Immunol 2006; 90:51 - 81; http://dx.doi.org/10.1016/S0065-2776(06)90002-9; PMID: 16730261
   PubMed Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, Vergati M, Steinberg SM, Tsang KY, et al. Overall survival (OS) analysis of a phase l trial of a vector-based vaccine (PSA-TRICOM) and ipilimumab (Ipi) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2010; 28:15s (suppl; abstr 2550).
   Google Scholar
• Lang JM, Staab MJ, Liu G, Wilding G, McNeel DG. Phase I dose-escalation trial of tremelimumab in combination with bicalutamide in patients with recurrent prostate cancer. J Clin Oncol 2011; 29: 16s (suppl; abstr 174).
   Google Scholar
• Kwon ED, Foster BA, Hurwitz AA, Madias C, Allison JP, Greenberg NM, et al. Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy. Proc Natl Acad Sci U S A 1999; 96:15074 - 9; http://dx.doi.org/10.1073/pnas.96.26.15074; PMID: 10611340
   PubMed Web of Science ®Google Scholar
• Chambers CA, Kuhns MS, Egen JG, Allison JP. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol 2001; 19:565 - 94; http://dx.doi.org/10.1146/annurev.immunol.19.1.565; PMID: 11244047
   PubMed Web of Science ®Google Scholar
• Beer TM, Slovin SF, Higano CS, Tejwani S, Dorff TB, Stankevich E, et al. Phase I trial of ipilimumab (IPI) alone and in combination with radiotherapy (XRT) in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2008; 26:13s (May 20 suppl; abstr 5004).
   Google Scholar
• Gerritsen W, van den Eertwegh AJ, de Gruijl T, van den Berg H, Scheper RJ, Sacks N, et al. Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC). J Clin Oncol 2008; 26: 13s (May 20 suppl; abstr 5146).
   Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711 - 23; http://dx.doi.org/10.1056/NEJMoa1003466; PMID: 20525992
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol 2010; 28:3167 - 75; http://dx.doi.org/10.1200/JCO.2009.26.7609; PMID: 20516446
   PubMed Web of Science ®Google Scholar
• McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, et al. Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 2009; 27:4047 - 54; http://dx.doi.org/10.1200/JCO.2008.19.9968; PMID: 19636017
   PubMed Web of Science ®Google Scholar
• Antonarakis ES, Zahurak M, Lin J, Keizman D, Carducci MA, Eisenberger MA. Changes in PSA kinetics predict metastasis-free survival in men with PSA-recurrent prostate cancer treated with non-hormonal agents. Cancer 2011; 118:1533-42.
   Google Scholar
• Becker JT, Olson BM, Johnson LE, Davies JG, Dunphy EJ, McNeel DG. DNA vaccine encoding prostatic acid phosphatase (PAP) elicits long-term T-cell responses in patients with recurrent prostate cancer. J Immunother 2010; 33:639 - 47; http://dx.doi.org/10.1097/CJI.0b013e3181dda23e; PMID: 20551832
   PubMed Web of Science ®Google Scholar
• Ciernik IF, Berzofsky JA, Carbone DP. Induction of cytotoxic T lymphocytes and antitumor immunity with DNA vaccines expressing single T cell epitopes. J Immunol 1996; 156:2369 - 75; PMID: 8786293
   PubMed Web of Science ®Google Scholar
• Donnelly JJ, Ulmer JB, Shiver JW, Liu MA. DNA vaccines. Annu Rev Immunol 1997; 15:617 - 48; http://dx.doi.org/10.1146/annurev.immunol.15.1.617; PMID: 9143702
   PubMed Web of Science ®Google Scholar
• Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008; 7:889 - 93; http://dx.doi.org/10.1586/14760584.7.7.889; PMID: 18767940
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J, Dipaola RS, Ko Y, Sweeney CJ, et al. Phase II prime/boost vaccination using poxviruses expressing PSA in hormone dependent prostate cancer: Follow-up clinical results from ECOG 7897. J Clin Oncol 2005;23:16s, (suppl; abstr 4501).
   Google Scholar
• DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med 2006; 4:1; http://dx.doi.org/10.1186/1479-5876-4-1; PMID: 16390546
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28:1099 - 105; http://dx.doi.org/10.1200/JCO.2009.25.0597; PMID: 20100959
   PubMed Web of Science ®Google Scholar
• Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci U S A 1993; 90:3539 - 43; http://dx.doi.org/10.1073/pnas.90.8.3539; PMID: 8097319
   PubMed Web of Science ®Google Scholar
• Jaffee EM, Lazenby A, Meurer J, Marshall F, Hauda KM, Counts C, et al. Use of murine models of cytokine-secreting tumor vaccines to study feasibility and toxicity issues critical to designing clinical trials. J Immunother Emphasis Tumor Immunol 1995; 18:1 - 9; http://dx.doi.org/10.1097/00002371-199507000-00001; PMID: 8535565
   PubMed Web of Science ®Google Scholar
• Simons JW, Carducci MA, Mikhak B, Lim M, Biedrzycki B, Borellini F, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer. Clin Cancer Res 2006; 12:3394 - 401; http://dx.doi.org/10.1158/1078-0432.CCR-06-0145; PMID: 16740763
   PubMed Web of Science ®Google Scholar
• Simons JW, Mikhak B, Chang JF, DeMarzo AM, Carducci MA, Lim M, et al. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res 1999; 59:5160 - 8; PMID: 10537292
   PubMed Web of Science ®Google Scholar
• Halabi S, Small EJ, Kantoff PW, Kattan MW, Kaplan EB, Dawson NA, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 2003; 21:1232 - 7; http://dx.doi.org/10.1200/JCO.2003.06.100; PMID: 12663709
   PubMed Web of Science ®Google Scholar
• Small EJ, Sacks N, Nemunaitis J, Urba WJ, Dula E, Centeno AS, et al. Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res 2007; 13:3883 - 91; http://dx.doi.org/10.1158/1078-0432.CCR-06-2937; PMID: 17606721
   PubMed Web of Science ®Google Scholar
• Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113:975 - 84; http://dx.doi.org/10.1002/cncr.23669; PMID: 18646045
   PubMed Web of Science ®Google Scholar
• Higano CS, Saad F, Somer B, Curti B, Petrylak D, Drake C, et al. A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). J Clin Oncol 2009;27:14s (suppl; abstr LBA150).
   Google Scholar
• Goldstein NS. Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores. Am J Clin Pathol 2002; 117:471 - 7; http://dx.doi.org/10.1309/G6PR-Y774-X738-FG2K; PMID: 11888088
   PubMed Web of Science ®Google Scholar
• Haines AM, Larkin SE, Richardson AP, Stirling RW, Heyderman E. A novel hybridoma antibody (PASE/4LJ) to human prostatic acid phosphatase suitable for immunohistochemistry. Br J Cancer 1989; 60:887 - 92; http://dx.doi.org/10.1038/bjc.1989.385; PMID: 2605098
   PubMed Web of Science ®Google Scholar
• U. S. Food and Drug Administration. Package insert (Provenge; Sipuleucel-T). http://www.fda.gov/downloads/BiologicsBloodVaccines/CellularGeneTherapyProducts/ApprovedProducts/UCM210031.pdf.
   Google Scholar
• Gryta T. Setback for Dendreon Cancer Drug. Wall Street Journal August 3, 2011.
   Google Scholar
• Small EJ, Fratesi P, Reese DM, Strang G, Laus R, Peshwa MV, et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18:3894 - 903; PMID: 11099318
   PubMed Web of Science ®Google Scholar
• So-Rosillo R, Small EJ. Sipuleucel-T (APC8015) for prostate cancer. Expert Rev Anticancer Ther 2006; 6:1163 - 7; http://dx.doi.org/10.1586/14737140.6.9.1163; PMID: 17020451
   PubMed Web of Science ®Google Scholar
• Burch PA, Croghan GA, Gastineau DA, Jones LA, Kaur JS, Kylstra JW, et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 2004; 60:197 - 204; http://dx.doi.org/10.1002/pros.20040; PMID: 15176049
   PubMed Web of Science ®Google Scholar
• Beinart G, Rini BI, Weinberg V, Small EJ. Antigen-presenting cells 8015 (Provenge) in patients with androgen-dependent, biochemically relapsed prostate cancer. Clin Prostate Cancer 2005; 4:55 - 60; PMID: 15992463
   PubMedGoogle Scholar
• Rini BI, Weinberg V, Fong L, Conry S, Hershberg RM, Small EJ. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer 2006; 107:67 - 74; http://dx.doi.org/10.1002/cncr.21956; PMID: 16736512
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089 - 94; http://dx.doi.org/10.1200/JCO.2005.04.5252; PMID: 16809734
   PubMed Web of Science ®Google Scholar
• Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009; 115:3670 - 9; http://dx.doi.org/10.1002/cncr.24429; PMID: 19536890
   PubMed Web of Science ®Google Scholar
• Liu EA. Biologics License Application (BLA) Medical Review 2007, FDA Submission Number: BLA125197.
   Google Scholar
• Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al, IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411 - 22; http://dx.doi.org/10.1056/NEJMoa1001294; PMID: 20818862
   PubMed Web of Science ®Google Scholar
• Gomella LG, Nabhan C, Whitmore JB, Frohlich MW, George DJ. Post-progression treatment with APC8015F may have prolonged survival of subjects in the control arm of sipuleucel-T phase III studies. J Clin Oncol 2011; 29: 16s (suppl; abstr 4534).
   Google Scholar
• Small EJ, Higano CS, Kantoff PW, Whitmore JB, Frohlich MW, Petrylak DP. Time to disease-related pain after sipuleucel-T in asymptomatic patients with metastatic castrate-resistant prostate cancer (mCRPC): Results from three randomized phase III trials. J Clin Oncol 2011; 29: 16s (suppl; abstr 4661).
   Google Scholar
• Sheikh NA, Wesley JD, Chadwick E, Perdue N, dela Rosa CP, Frohlich MW, Stewart FP, Urdal DL. Characterization of antigen-specific T-cell activation and cytokine expression induced by sipuleucel-T. J Clin Oncol 2011; 29: 16s (suppl; abstr 155).
   Google Scholar
• McLeod DG, Quinn DI, Whitmore M, Tabesh M. Sipuleucel-T in African Americans: A subgroup analysis of three phase III sipuleucel-T in advanced prostate cancer. J Clin Oncol 2011; 29: 16s (suppl; abstr 15148).
   Google Scholar
• Pak S, Reed M, Luther M, Averia M, Desai S, Pinski JK, et al. Evaluation of patients, safety, and financial implications of sipuleucel-T(Sip T) for treatment of metastatic castrate-resistant prostate cancer(mCRPC): Early real-world experience at USC. J Clin Oncol 2011; 29: 16s (suppl; abstr 15124).
   Google Scholar
• Beer TM, Bernstein GT, Corman JM, Glode LM, Hall SJ, Poll WL, et al. Randomized trial of autologous cellular immunotherapy with sipuleucel-T in androgen-dependent prostate cancer. Clin Cancer Res 2011; 17:4558 - 67; http://dx.doi.org/10.1158/1078-0432.CCR-10-3223; PMID: 21558406
   PubMed Web of Science ®Google Scholar
• Beer TM, Schellhammer PF, Corman JM, Glode LM, Hall S, Xu Y, et al. Quality-of-life assessment in a randomized, double-blind study of sipuleucel-T in men with androgen-dependent prostate cancer. J Clin Oncol 2011; 29: (suppl; abstr 4648).
   Google Scholar
• Antonarakis ES, Kibel AS, Lin DW, Tyler RC, Tabesh M, Drake CG. Design of an open-label randomized phase II trial examining the effect of sequencing of sipuleucel-T androgen deprivation therapy (ADT) on immune markers in prostate cancer patients with a rising prostate specific antigen (PSA) after primary therapy. J Clin Oncol 2011; 29: 16s (suppl; abstr TPS189).
   Google Scholar
• Fizazi K, Powles T, George DJ, Poehlein CH. A randomized, controlled phase III global trial comparing sipuleucel-T plus androgen deprivation therapy versus androgen deprivation therapy alone in men with metastatic androgen dependent (hormone sensitive) prostate cancer. J Clin Oncol 2011; 29: 16s (suppl; abstr TPS188).
   Google Scholar
• Makarov DV, Humphreys EB, Mangold LA, Carducci MA, Partin AW, Eisenberger MA, et al. The natural history of men treated with deferred androgen deprivation therapy in whom metastatic prostate cancer developed following radical prostatectomy. J Urol 2008; 179:156 - 61, discussion 161-2; http://dx.doi.org/10.1016/j.juro.2007.08.133; PMID: 18001801
   PubMed Web of Science ®Google Scholar
• Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, et al. Improved endpoints for cancer immunotherapy trials. J Natl Cancer Inst 2010; 102:1388 - 97; http://dx.doi.org/10.1093/jnci/djq310; PMID: 20826737
   PubMed Web of Science ®Google Scholar
• Cha E, Fong L. Immunotherapy for prostate cancer: biology and therapeutic approaches. J Clin Oncol 2011; 29:3677 - 85; http://dx.doi.org/10.1200/JCO.2010.34.5025; PMID: 21825260
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010; 59:663 - 74; http://dx.doi.org/10.1007/s00262-009-0782-8; PMID: 19890632
   PubMed Web of Science ®Google Scholar
• Nilsson S, O'Bryan-Tear CG, Bolstad B, Lokna A, Parker C. Alkaline phosphatase (ALP) normalization and overall survival in patients with bone metastases from castration-resistant prostate cancer (CRPC) treated with radium-223. J Clin Oncol 2011; 29: 16s (suppl; abstr 4620).
   Google Scholar
• Madan RA, Gulley JL, Schlom J, Steinberg SM, Liewehr DJ, Dahut WL, et al. Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res 2008; 14:4526 - 31; http://dx.doi.org/10.1158/1078-0432.CCR-07-5048; PMID: 18628467
   PubMed Web of Science ®Google Scholar
• Naito M, Itoh K, Komatsu N, Yamashita Y, Shirakusa T, Yamada A, et al. Dexamethasone did not suppress immune boosting by personalized peptide vaccination for advanced prostate cancer patients. Prostate 2008; 68:1753 - 62; http://dx.doi.org/10.1002/pros.20847; PMID: 18767041
   PubMed Web of Science ®Google Scholar
• Pollack A. New drugs fight prostate cancer, but at high cost. New York Times. June 27, 2011.
   Google Scholar
• Horgan AM, Bradbury PA, Amir E, Ng R, Douillard JY, Kim ES, et al. An economic analysis of the INTEREST trial, a randomized trial of docetaxel versus gefitinib as second-/third-line therapy in advanced non-small-cell lung cancer. Ann Oncol 2011; 22:1805 - 11; http://dx.doi.org/10.1093/annonc/mdq682; PMID: 21273345
   PubMed Web of Science ®Google Scholar
• Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, et al, TAX 327 Investigators. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351:1502 - 12; http://dx.doi.org/10.1056/NEJMoa040720; PMID: 15470213
   PubMed Web of Science ®Google Scholar
• Paller CJ, Antonarakis ES. Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer. Drug Des Devel Ther 2011; 5:117 - 24; PMID: 21448449
   PubMed Web of Science ®Google Scholar
• Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26:242 - 5; http://dx.doi.org/10.1200/JCO.2007.12.4008; PMID: 18182665
   PubMed Web of Science ®Google Scholar